(S) -10-Hydroxycamptothecine-d5

(S) -10-Hydroxycamptothecin-d5 (10-HCPT-d5) is the deuterium labeled (S) -10-Hydroxycamptothecin. (S) -10-Hydroxycamptothecin (10-HCPT) is a DNA topoisomerase I inhibitor. (S) -10-Hydroxycamptothecin exhibits a remarkable apoptosis-inducing effect. (S) -10-Hydroxycamptothecin has the potential for hepatoma, gastric carcinoma, colon cancer and leukaemia research[1][2][3][4].

1330277-66-1

10-HCPT-d5; 10-Hydroxycamptothecin-d5

12352005

Apoptosis; Isotope-Labeled Compounds; Topoisomerase

Apoptosis; Cell Cycle/DNA Damage; Others

Cancer-programmed cell death

Cancer

10 mM in DMSO

O=C1N2C(C=3C(C2)=CC=4C(N3)=CC=C(O)C4)=CC5=C1COC(=O)[C@@]5(C(C([2H])([2H])[2H])([2H])[2H])O

C20H11D5N2O5

369.38

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Min Liu, et al. Intracellular delivery of 10-hydroxycamptothecin
 with targeted nanostructured lipid carriers against
 multidrug resistance
 . Journal of Drug Targeting.|[3]Min Liu, et al. Intracellular delivery of 10-hydroxycamptothecin with targeted
 nanostructured lipid carriers against multidrug resistance. J Drug Target, Early Online: 1–8|[4]Yu P, et al. Synthesis and preliminary anticancer evaluation of 10-hydroxycamptothecin analogs. Biol Pharm Bull. 2012;35 (8) :1295-9.|[5]Zhang XW, et al. Differentiation-inducing action of 10-hydroxycamptothecin on human hepatoma Hep G2 cells. Acta Pharmacol Sin. 2000 Apr;21 (4) :364-8.|[6]Zhang XW, et al. Differential regulation of P53, c-Myc, Bcl-2, Bax and AFP protein expression, and caspase activity during 10-hydroxycamptothecin-induced apoptosis in Hep G2 cells. Anticancer Drugs. 2000 Oct;11 (9) :747-56.|[7]Liu M, et al. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance. J Drug Target. 2016;24 (5) :433-40.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-N0095S/

Isotope-Labeled Compounds

No Development Reported